Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Citigroup Issues Pessimistic Forecast for Intuitive Surgical (NASDAQ ...

📉 Citigroup reduced its price target for Intuitive Surgical from $590.00 to $500.00 while maintaining a 'buy' rating.

📉 BTIG Research, Robert W. Baird, and Sanford C. Bernstein also lowered their respective price targets on Friday.

📈 The company reported Q1 EPS of $2.50, beating the consensus estimate of $2.08 by $0.42.

💰 Revenue reached $2.77 billion for the quarter, up 23% year-over-year against a consensus of $2.62 billion.

📊 Intuitive Surgical achieved a net margin of 28.45% and a return on equity of 17.09% in the latest quarter.

👔 EVP Gary Loeb sold 400 shares worth $169,656 under a Rule 10b5-1 trading plan on June 10th.

👔 SVP Iman Jeddi sold 5,625 shares worth $2.37 million under a pre-arranged plan on June 1st.

📈 Regent Peak Wealth Advisors increased its stake by 7.2% to own 800 shares valued at $318,000.

📈 Hyperion Asset Management lifted its position by 49.8%, now holding 419,329 shares worth $166.76 million.

📈 Northside Capital Management initiated a new stake valued at $669,000 during the second quarter.

🏦 Institutional investors and hedge funds own 83.64% of the company's outstanding stock.

🔮 Analysts anticipate Intuitive Surgical will post $8.62 EPS for the current fiscal year.

Bullish Signals
  • Intuitive Surgical reported revenue of $2.77 billion, which beat the consensus estimate of $2.62 billion by $150 million.
  • The company achieved a net margin of 28.45% and a return on equity of 17.09%, indicating strong operational efficiency.
  • Quarterly revenue grew 23% year-over-year, demonstrating sustained demand for the da Vinci surgical systems.
  • Major institutional investors like Hyperion Asset Management increased their holdings by nearly 50% in the second quarter.
  • Analysts anticipate an EPS of $8.62 for the current fiscal year, reflecting continued growth expectations.
  • Despite recent insider sales, a significant majority of shares (83.64%) are held by institutional investors and hedge funds.
Risk Factors
  • Citigroup reduced its price target from $590 to $500, citing potential valuation concerns despite maintaining a buy rating.
  • Multiple other analysts including BTIG Research, Robert W. Baird, and Sanford C. Bernstein recently lowered their price targets.
  • Executives Gary Loeb and Iman Jeddi sold a combined total of over $3 million in shares during June under pre-arranged plans.
Full Analysis
Intuitive Surgical (NASDAQ:ISRG) faces a mixed analyst outlook following a cluster of price target reductions from major brokerages on Friday. Citigroup lowered its target from $590 to $500, while BTIG Research, Robert W. Baird, and Sanford C. Bernstein also cut their targets to $469, $500, and $685 respectively, though most maintained 'buy' or 'outperform' ratings. Conversely, HSBC recently decreased its target but kept a buy rating, highlighting a divergence in analyst sentiment regarding the stock's immediate valuation. The company reported strong quarterly financial results on April 21st, beating consensus estimates with $2.50 EPS and $2.77 billion in revenue, representing a 23% year-over-year increase. The firm achieved a net margin of 28.45% and a return on equity of 17.09%, demonstrating robust profitability despite the recent analyst downgrades. Analysts anticipate an EPS of $8.62 for the current fiscal year, suggesting continued growth expectations persist among the investment community. Insider trading activity shows mixed signals with executives Gary Loeb and Iman Jeddi selling shares under pre-arranged Rule 10b5-1 plans in June, totaling over $3 million in sales. However, institutional ownership remains high at 83.64%, with significant additions from Regent Peak Wealth Advisors, Hyperion Asset Management, and Northside Capital Management during the second quarter, indicating continued confidence from large capital holders despite recent insider offloading.